<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00517218</url>
  </required_header>
  <id_info>
    <org_study_id>GL305</org_study_id>
    <nct_id>NCT00517218</nct_id>
  </id_info>
  <brief_title>This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)</brief_title>
  <official_title>A Randomized Phase 3 Study of Fludarabine and Rituximab With or Without Genasense® (Oblimersen Sodium) in Previously Untreated Subjects With Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genta Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genta Incorporated</source>
  <brief_summary>
    <textblock>
      To compare the efficacy and safety of combination treatment with Genasense, fludarabine, and
      rituximab versus combination treatment with fludarabine and rituximab in previously untreated
      subjects with CLL.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>June 2006</start_date>
  <completion_date>June 2009</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Genasense® (, oblimersen sodium G3139)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Previously untreated subjects with intermediate-or high-risk CLL(modified Rai Stages
             I-IV)

          -  Measurable disease as primarily established by the National Cancer Institute-sponsored
             Working Group(NCI-WG) Guidelines for the diagnosis of CLL

          -  Requiring therapy for active disease, as primarily defined by the NCI-WG Guidelines

          -  Eastern Cooperative Oncology Group Performance Status &lt; 2

          -  Adequate organ function determined , 14 days prior to the first dose of study
             medication

        Exclusion Criteria:

          -  Absolute Lymphocyte count &gt; 100,000/uL

          -  Prior chemotherapy or other therapy for CLL, including allogeneic transplant

          -  Less than 3 weeks from any prior major surgery at the time of informed consent

          -  Failure to recover from any serious adverse effect of surgery

          -  History of autoimmune hemolytic anemia or autoimmune thrombocytopenia

          -  Active serious infection requiring systemic anti-infective therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2007</study_first_submitted>
  <study_first_submitted_qc>August 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2007</study_first_posted>
  <last_update_submitted>February 7, 2008</last_update_submitted>
  <last_update_submitted_qc>February 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2008</last_update_posted>
  <keyword>Evaluate the Effect of Genasense on the Efficacy/Safety of Rituximab/Fludarabine Treatment in Untreated Subjects With Chronic Lymphocyctic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Oblimersen</mesh_term>
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

